Aligning Science Across Parkinson's Logo Text

Constitutive nuclear accumulation of endogenous alpha-synuclein in mice causes motor impairment and cortical dysfunction, independent of protein aggregation

Output Details

Preprint October 14, 2021

Published February 18, 2022

A growing body of evidence suggests that nuclear alpha-synuclein (αSyn) plays a role in the pathogenesis of Parkinson’s disease (PD). However, this question has been difficult to address as controlling the localization of αSyn in experimental systems often requires protein overexpression, which affects its aggregation propensity. To overcome this, we engineered SncaNLS mice, which localize endogenous αSyn to the nucleus. We characterized these mice on a behavioral, histological and biochemical level to determine whether the increase of nuclear αSyn is sufficient to elicit PD-like phenotypes. SncaNLS mice exhibit age-dependent motor deficits and altered gastrointestinal function. We found that these phenotypes were not linked to αSyn aggregation or phosphorylation. Through histological analyses, we observed motor cortex atrophy in the absence of midbrain dopaminergic neurodegeneration. We sampled cortical proteomes of SncaNLS mice and controls to determine the molecular underpinnings of these pathologies. Interestingly, we found several dysregulated proteins involved in dopaminergic signaling, including Darpp32, Pde10a and Gng7, which we further confirmed was decreased in cortical samples of the SncaNLS mice compared with controls. These results suggest that chronic endogenous nuclear αSyn can elicit toxic phenotypes in mice, independent of its aggregation. This model raises key questions related to the mechanism of αSyn toxicity in PD and provides a new model to study an under-appreciated aspect of PD pathogenesis.
Identifier (DOI)
10.1093/hmg/ddac035
Tags
  • Mouse
  • Original Research
  • SNCA

Meet the Authors

  • User avatar fallback logo

    Haley Geertsma

    External Collaborator

  • User avatar fallback logo

    Terry Suk

    External Collaborator

  • User avatar fallback logo

    Konrad Ricke

    External Collaborator

  • User avatar fallback logo

    Kyra Horsthuis

    External Collaborator

  • User avatar fallback logo

    Jean-Louis Parmasad

    External Collaborator

  • User avatar fallback logo

    Zoe Fisk

    External Collaborator

  • User avatar fallback logo

    Steve Callaghan

    External Collaborator

  • Maxime Rousseaux, PhD

    Co-PI (Core Leadership): Team Schlossmacher

    The Ottawa Hospital

Aligning Science Across Parkinson's
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.